(Q51488952)

English

Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.

scientific article published in November 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

1 reference

based on heuristic

inferred from title

Lars L. Gustafsson

8

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

author name string

Arlander E

1

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

Ekström G

2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

Alm C

3

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

Carrillo JA

4

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

Bielenstein M

5

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

Böttiger Y

6

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

Bertilsson L

7

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

language of work or name

0 references

publication date

1 November 1998

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

64

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

5

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

484-491

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Lack of metabolic racemisation of ropivacaine, determined by liquid chromatography using a chiral AGP column.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Intraindividual and interindividual variability in the disposition of the local anesthetic ropivacaine in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

The use of ketoconazole as an inhibitor of steroid production

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Determination of free concentration of ropivacaine and bupivacaine in blood plasma by ultrafiltration and coupled-column liquid chromatography.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990131-X

7 January 2021

Identifiers

10.1016/S0009-9236(98)90131-X

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/9834040

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51488952&oldid=1508397577"